SavedAdd your journal

Journals / Toraks Dergisi / 2007 / Cilt: 8 - Sayı: 4

Differential diagnosis of malignant mesothelioma versus pulmonary adenocarcinoma: An immunohistochemical analysis

Akciğer adenokarsinomu ve malign mezotelyoma ayırıcı tanısında immünhistokimyasal analiz

EKREM CENGİZ SEYHAN
ERDOĞAN ÇETİNKAYA
Sedat ALTIN
Nur ÜRER
Sinem TİMUR
Pages
202–206
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CEA and CD 15 can be used as negative antibodies, and calretinin and mesothelin as positive antibodies in the diferential diagnosis of pleural mesothelioma and adenocarcinoma of the lung.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we evaluated CEA, CD 15, calretinin, and mesothelin in the differential diagnosis of pleural mesothelioma and adenocarcinoma of the lung.
📊
Key Findings & Data:Sixtyone malignant mesothelioma and 48 lung adenocarcinoma cases were studied.
💡
Conclusion & Impact:CEA and CD 15 can be used as negative antibodies, and calretinin and mesothelin as positive antibodies in the diferential diagnosis of pleural mesothelioma and adenocarcinoma of the lung.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tanı · ayırıcı · Adenokarsinom

Abstract

In this study, we evaluated CEA, CD 15, calretinin, and mesothelin in the differential diagnosis of pleural mesothelioma and adenocarcinoma of the lung. Sixtyone malignant mesothelioma and 48 lung adenocarcinoma cases were studied. Commercial antibodies to calretinin, mesothelin, CEA, and CD 15 were applied using the streptavidin-biotin-peroxidase complex procedure on formalin-fixed, paraffin wax-embedded tissue. According to our results, sensitivity and specificity in the diagnosis of mesothelioma was 86% and 81%, respectively for calretinin, and 68% and 81%, respectively for mesothelin. Sensitivity and specificity in the diagnosis of adenocarcinoma was 85% and 81% respectively for CEA, and 62% and 90% respectively for CD 15. CEA and CD 15 can be used as negative antibodies, and calretinin and mesothelin as positive antibodies in the diferential diagnosis of pleural mesothelioma and adenocarcinoma of the lung.

Özet

Çalışmamızda malign mezotelyoma (MM) ile akciğer adenokarsinoma (AC) ayrımında kalretinin, mezotelin, karsinoembriyojenik antijen (CEA) ve CD 15 antikorlarının katkısını araştırmak amaçlanmıştır. Histopatolojik incelemeler ile tanısı konulmuş 48 akciğer AC ve 61 MM olgusunun parafin blok örneklerine immunohistokimyasal olarak standart avidin- biotin tekniği ile kalretinin, mezotelin, CEA ve CD-15 karşı antikorlar uygulanmıştır. Elde edilen bulgulara göre kalretinin, MM’lı olguları saptamadaki duyarlılığı ve özgüllüğü; %86 ve %81, mezotelinin ise; %68 ve %81 olarak hesaplanmıştır. CEA antikorlarının AC’lu olguları saptamadaki duyarlılığı ve özgüllüğü sırasıyla %85 ve %81, CD 15 antikorlarının ise %62 ve %90 olarak bulunmuştur. Mezotelin ve kalretinin pozitif, CEA ve CD-15’in negatif boyama gösteren antikorlar olarak AC ile MM ayrımında kullanılabileceği sonucuna varılmıştır

🔖

Cite This Article

SEYHAN, E. C., ÇETİNKAYA, E., ALTIN, S., ÜRER, N., TİMUR, S. (2007). Differential diagnosis of malignant mesothelioma versus pulmonary adenocarcinoma: An immunohistochemical analysis. Toraks Dergisi, Cilt: 8 - Sayı: 4, 202–206. https://ajindex.com/articles/368153

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Carella R, Deleonardi G, Errico AD. Immunohistochemical panels for differentiating epithelial mesothelioma from adenocarcinoma. Am J Surg Pathol 2001; 25: 43-50
  2. Oates J, Edwards C. HBME-1, MOC-31, WT-1 and calretinin an assesment of recently described markers for mesothelioma and adenocarsinoma. Histopathology 2000; 36: 341-7
  3. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differantiation between mesothhelioma from adenocarcinoma. Histopathology 1998; 32: 209-16
  4. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA19-9, HMBE-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998; 84: 101-8
  5. Abutaily AS, Addis BJ, Roche WR. Immunhistochemistry in the distinction between malignant mesothelioma and lung adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002; 55: 662-8
  6. Ordonez NG. The immunohistochemical diagnosis of meshotelioma: a comparative study of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003; 27: 1031-51
  7. Comin CE, Novelli L, Boddi V et al. Calretinin, Thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating mesothelioma from pulmonary adenocarcinoma. Hum Pathol 2001; 32: 529-32
  8. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopatholgy 1997; 30: 403-18
  9. Wick RM. Immunphenotyping of malignant mesothelioma. Am J Surg Pathol 1997; 21: 1395-98
  10. Ordonez NG. Value of the calretinin immunostanding in differentiating epithelial pleural meshothelioma from adenocarcinoma. Mod Pathol 1998; 11: 929-33
  11. Yaziji H, Battifora H, Barry TS et al. Evaliation of 12 antibodies for distinguishing epithelial meshothelioma from adenocarcinoma. Mod Pathol 2006; 19: 514-23
  12. Cury PM, Butcher DN, Fisher C et al. Value of mesothelium- associated antibodies thrombomodulin, cytoceratin 5/6, and calretinin in distinguishing meshothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000; 13: 107-12
  13. Robinson BW, Creaney J, Lake R et al. Mesothelin- family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6
  14. Doglini C, Tos AP, Laurino N et al. Calretinin: a novel immuncytochemical marker for meshotelioma. Am J Surg Pathol 1996; 20: 1037-46
  15. Roges J, Khan M, Ellis J. Calretinin and other Ca binding proteins in the nervous system. Adv Exp Med Biol 1990; 269: 195-203
  16. Aydıner F, Yerici O